NEW DELHI: Mumbai-based JB Chemical compounds will purchase choose ophthalmology manufacturers from Swiss main Novartis for $116 million (Rs 964 crore) to enter the high-growth eyecare market. The settlement will come into impact from January 2027.
Until then, the corporate has entered right into a promotion and distribution settlement for a similar manufacturers with Novartis for 3 years beginning December 2023.JB Pharma can pay an extra Rs 125 crore for the distribution settlement, taking over the deal measurement to Rs 1,089 crore.
The deal was first reported by TOI in its December 11 version. The manufacturers embrace Simbrinza, Travacom, Azopt, Travatan and Vigamox. As per IQVIA, MAT September 2023 information, gross sales for the opthal portfolio stood at Rs 207 crore.
Ophthalmology is among the quickest rising therapies within the home pharma market and this deal will catapult JB Chemical compounds to the main gamers within the ophthalmology section, the corporate stated in an alternate submitting on December 19. Eight of the ten medicine which have been acquired are rising between 10% and 20% (three years’ CAGR).
Until then, the corporate has entered right into a promotion and distribution settlement for a similar manufacturers with Novartis for 3 years beginning December 2023.JB Pharma can pay an extra Rs 125 crore for the distribution settlement, taking over the deal measurement to Rs 1,089 crore.
The deal was first reported by TOI in its December 11 version. The manufacturers embrace Simbrinza, Travacom, Azopt, Travatan and Vigamox. As per IQVIA, MAT September 2023 information, gross sales for the opthal portfolio stood at Rs 207 crore.
Ophthalmology is among the quickest rising therapies within the home pharma market and this deal will catapult JB Chemical compounds to the main gamers within the ophthalmology section, the corporate stated in an alternate submitting on December 19. Eight of the ten medicine which have been acquired are rising between 10% and 20% (three years’ CAGR).
